Samson Yashar Sharam, Gielczyk Robert, Scherschun Lubomira, Lim Henry W
Department of Dermatology, Henry Ford Health System, Detroit, MI 48202, USA.
Photodermatol Photoimmunol Photomed. 2003 Aug;19(4):164-8. doi: 10.1034/j.1600-0781.2003.00039.x.
Narrow-band ultraviolet B (NB-UVB) therapy has been used successfully for the treatment of inflammatory and pigmentary skin disorders including atopic dermatitis, psoriasis, mycosis fungoides, polymorphous light eruption, and vitiligo.
This is a retrospective review of the treatment outcomes of 117 consecutive patients with vitiligo, pruritus, and other inflammatory dermatoses, excluding those with psoriasis and CTCL, who were treated with NB-UVB between 1998 and 2001 at our institution.
Approximately 80% of all patients showed improvement in their condition. NB-UVB phototherapy was well tolerated, with no serious adverse effects. In patients with vitiligo, 6.4% had an abnormal thyroid-stimulating hormone level and 6.5% had anemia.
NB-UVB may be considered as a viable therapeutic option in the treatment of vitiligo, pruritus, and other inflammatory dermatoses. Long-term adverse effects and cost-benefit analysis of NB-UVB therapy compared to other treatment modalities remain to be determined.
窄谱中波紫外线（NB-UVB）疗法已成功用于治疗包括特应性皮炎、银屑病、蕈样肉芽肿、多形性日光疹和白癜风在内的炎症性和色素性皮肤病。
这是一项对117例连续患有白癜风、瘙痒症及其他炎症性皮肤病患者治疗结果的回顾性研究，排除了1998年至2001年在我们机构接受NB-UVB治疗的银屑病和皮肤T细胞淋巴瘤患者。
约80%的患者病情有所改善。NB-UVB光疗耐受性良好，无严重不良反应。白癜风患者中，6.4%促甲状腺激素水平异常，6.5%有贫血。
NB-UVB可被视为治疗白癜风、瘙痒症及其他炎症性皮肤病的一种可行治疗选择。与其他治疗方式相比，NB-UVB疗法的长期不良反应及成本效益分析仍有待确定。
